The companies are facing over 3,500 opioid-related lawsuits.
LinkedIn examined companies in 10 growing markets across the US.
Berkshire disclosed an $8.6 billion stake in Verizon Communications and a $4.1 billion position in Chevron Corp.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
| Website: | www.abbvie.com |
| Email: | liz.shea@abbvie.com |
| Main Phone: | +1 847 932-7900 |
| Address: | 1 North Waukegan Road |
| State: | IL |
| City / Town: | North Chicago |
| Country: | US |
| Postal Code: | 60064-6400 |
| Exchange: | NYE |
| CEO: | Richard A. Gonzalez |
| Employees: | 47000 |
| Issuer Type: | CS - Common Stock |
| Sector/Industry: | Healthcare |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The companies are facing over 3,500 opioid-related lawsuits.
LinkedIn examined companies in 10 growing markets across the US.
Berkshire disclosed an $8.6 billion stake in Verizon Communications and a $4.1 billion position in Chevron Corp.
Nearly all the increases were below 10%, and the median hike was 4.8%, down slightly from the previous year.
Berkshire disclosed $5.7 billion of new healthcare stakes, including more than $1.8 billion each in Abbvie, Bristol-Myers Squibb and Merck and $136 million in Pfizer.
AbbVie is among 12 companies that have been asked for information by the committee, but it's the only whose responses have been found wanting.
NY has charged the pharmaceutical firms with downplaying the risks of their opioid painkillers to patients and doctors.
AbbVie is paying $750 million upfront to jointly develop and commercialize three of Genmab’s antibodies, including its blood cancer treatment candidate, epcoritamab, currently in a mid-stage study.
Bloomberg News reported the contact and that Gilead did not express interest in a merger.
The $63 billion deal, which is expected to close this quarter, was approved by the European Union in January.
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
